Literature DB >> 11929777

Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4.

Saroj K Basak1, Airi Harui, Marina Stolina, Sherven Sharma, Kohnosuke Mitani, Steven M Dubinett, Michael D Roth.   

Abstract

Dendritic cells (DCs) are rare antigen-presenting cells that play a central role in stimulating immune responses. The combination of recombinant granulocyte macrophage-colony-stimulating factor (rGM-CSF) and recombinant interleukin-4 (rIL-4) provides an important stimulus for generating DCs from murine bone marrow precursors in vitro. Using miniature osmotic pumps, we now demonstrate that continuous infusion of these cytokines for 7 days had a similar effect in vivo, increasing the number and function of splenic DCs. Administration of rGM-CSF/rIL-4 (10 microg/d each) increased the concentration of CD11(+) DCs by 2.7-fold and the absolute number of splenic DCs by an average of 5.7-fold. DC number also increased in peripheral blood and lymph nodes. The resultant DCs exhibited a different phenotype and function than those in control mice or mice treated with rGM-CSF alone. rGM-CSF/IL-4 increased both the myeloid (CD11c(+)/CD11b(+)) and the lymphoid (CD11c(+)/CD8alpha(+)) subpopulations, whereas rGM-CSF increased only myeloid DCs. DCs were highly concentrated in the T-cell areas of white pulp after rGM-CSF/IL-4 administration, whereas they were diffusely distributed throughout white pulp, marginal zones, and red pulp in mice treated with rGM-CSF alone. rGM-CSF/rIL-4 also significantly increased the expression of major histocompatibility complex (MHC) class I and MHC class II on CD11c(+) cells and increased their capacity to take up antigens by macropinocytosis and receptor-mediated endocytosis. Splenic DCs generated in response to rGM-CSF/rIL-4 were functionally immature in terms of allostimulatory activity, but this activity increased after short-term in vitro culture. Systemic treatment with rGM-CSF/rIL-4 enhanced the response to an adenoviral-based vaccine and led to antigen-specific retardation in the growth of established tumor. We conclude that systemic therapy with the combination of rGM-CSF/rIL-4 provides a new approach for generating DCs in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929777     DOI: 10.1182/blood.v99.8.2869

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  A novel osteoclast precursor cell line, 4B12, recapitulates the features of primary osteoclast differentiation and function: enhanced transfection efficiency before and after differentiation.

Authors:  Shigeru Amano; Keisuke Sekine; Lynda F Bonewald; Yoshihiro Ohmori
Journal:  J Cell Physiol       Date:  2009-10       Impact factor: 6.384

2.  Clonal analysis of human dendritic cell progenitor using a stromal cell culture.

Authors:  Jaeyop Lee; Gaëlle Breton; Arafat Aljoufi; Yu Jerry Zhou; Sarah Puhr; Michel C Nussenzweig; Kang Liu
Journal:  J Immunol Methods       Date:  2015-06-06       Impact factor: 2.303

3.  Differential modulation in the functions of intestinal dendritic cells by long- and medium-chain fatty acids.

Authors:  Yoshikazu Tsuzuki; Jyunichi Miyazaki; Koji Matsuzaki; Yoshikiyo Okada; Ryota Hokari; Atsushi Kawaguchi; Shigeaki Nagao; Kazuro Itoh; Soichiro Miura
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

4.  Tumor antigen-pulsed CD8α(+) dendritic cells induce T cell-mediated graft-versus-tumor effect in vitro.

Authors:  Ning Na; Kang Chen; Jian Zhang; Shanyang He; Qiang Fu; Beili Zhu; Kaiyuan Cao; Lin Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

5.  Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production.

Authors:  Sandesh Subramanya; Sang-Soo Kim; Sojan Abraham; Jiahong Yao; Mukesh Kumar; Priti Kumar; Viraga Haridas; Sang-Kyung Lee; Leonard D Shultz; Dale Greiner; Manjunath N; Premlata Shankar
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

6.  Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.

Authors:  Stephen C Jones; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells.

Authors:  X Zhang; P Zhao; C Kennedy; K Chen; J Wiegand; G Washington; L Marrero; Y Cui
Journal:  Cancer Gene Ther       Date:  2007-12-14       Impact factor: 5.987

8.  Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.

Authors:  Sachin M Apte; Saroj Vadhan-Raj; Lorenzo Cohen; Roland L Bassett; Ilyssa O Gordon; Charles F Levenback; Pedro T Ramirez; Stacie T Gallardo; Rebecca S Patenia; Michael E Garcia; Revathy B Iyer; Ralph S Freedman
Journal:  J Transl Med       Date:  2006-04-07       Impact factor: 5.531

9.  An alternative flow cytometry strategy for peripheral blood dendritic cell enumeration in the setting of repetitive GM-CSF dosing.

Authors:  Kehui Wang; Kevin P Nishimoto; Rita S Mehta; Edward L Nelson
Journal:  J Transl Med       Date:  2006-04-24       Impact factor: 5.531

10.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.